EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Intensification of upfront chemotherapy for patients with myeloid blast phase CML: a single center experience

Benjamin J Lee iD, Shawn P Griffin iD, Jean Doh iD, Stefan O Ciurea iD, Deepa Jeyakumar iD, Piyanuch Kongtim iD, Kiran Naqvi iD

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-06045-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, 2024. Verfasst von Benjamin J Lee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Chao Family Comprehensive Cancer Center, University of California Irvine Health, 101 The City Drive South, Bldg. 23, Rm 275, …. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Blast Crisis, Cytarabine, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Outcomes for patients with myeloid blast phase chronic myeloid leukemia (CML-MBP) are dismal, and no preferred chemotherapy regimen has been identified. Recent studies have suggested a higher response rate with administration of timed-sequenced regimens (TSR) (purine analog, high-dose cytarabine, anthracycline) in high-risk acute myeloid leukemia patients. We retrospectively evaluated outcomes of newly diagnosed CML-MBP patients consecutively treated at our institution with a TSR or standard-dose cytarabine and an anthracycline (“7 + 3”) combined with a tyrosine-kinase inhibitor (TKI) between 2011 and 2023. Endpoints of interest included hematologic response, clinically significant cytogenetic response (CSCR) defined as achieving at least a minor cytogenetic response (Ph + metaphases 0%-≤65%) after induction therapy, event-free survival (EFS), and overall survival (OS). A total of 18 patients with CML-MBP were included of whom 9 (50%) received a TSR and 9 (50%) received “7 + 3”. Hematologic response (55.6% vs. 55.6%) and CSCR (25% vs. 37.5%) were similar between TSR- and “7 + 3” treated patients. Twelve patients (66.7%) experienced at least one grade ≥ 3 non-hematologic, end-organ toxicity with 33.3% and 11.1% of TSR- and 7 + 3-treated patients, respectively, experiencing at least two. Our data suggests that intensification of upfront chemotherapy does not appear to improve treatment outcomes in CML-MBP patients however, further studies are warranted to confirm these findings involving a larger cohort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBlast CrisisCytarabineLeukemia, Myelogenous, Chronic, BCR-ABL PositiveHumansMaleFemaleMiddle AgedAdultRetrospective StudiesAgedProtein Kinase InhibitorsAnthracyclinesTreatment OutcomeDisease-Free SurvivalSurvival Rate

Stichwörter der Autor:innen

Blast-phase CMLChronic myeloid leukemiaMyeloid blast crisisTyrosine kinase inhibitor“7 + 3” chemotherapy

Substanzen

CytarabineProtein Kinase InhibitorsAnthracyclines

Autor:innen und Institutionen

  • Department of Pharmacy, Chao Family Comprehensive Cancer Center, University of California Irvine Health, 101 The City Drive South, Bldg. 23, Rm 275, Orange, CA, 92868, USA. benjaml9@hs.uci.edu.
  • Department of Clinical Pharmacy Practice, School of Pharmacy & Pharmaceutical Sciences, University of California, Irvine, CA, USA. benjaml9@hs.uci.edu.
  • Department of Pharmacy, Chao Family Comprehensive Cancer Center, University of California Irvine Health, 101 The City Drive South, Bldg. 23, Rm 275, Orange, CA, 92868, USA.
  • Department of Clinical Pharmacy Practice, School of Pharmacy & Pharmaceutical Sciences, University of California, Irvine, CA, USA.
  • Department of Medicine, Division of Hematology Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Health, Orange, CA, USA.

ORCID-Profile: Benjamin J Lee, Shawn P Griffin, Jean Doh, Stefan O Ciurea, Deepa Jeyakumar, Piyanuch Kongtim, Kiran Naqvi

Förderung

  • NCI NIH HHS

Zitieren

APA

Lee, B. J., Griffin, S. P., Doh, J., Ciurea, S. O., Jeyakumar, D., Kongtim, P., & Naqvi, K. (2024). Intensification of upfront chemotherapy for patients with myeloid blast phase CML: a single center experience. Annals of Hematology. https://doi.org/10.1007/s00277-024-06045-8

Vancouver

Lee BJ, Griffin SP, Doh J, Ciurea SO, Jeyakumar D, Kongtim P, et al. Intensification of upfront chemotherapy for patients with myeloid blast phase CML: a single center experience. Annals of Hematology. 2024. doi:10.1007/s00277-024-06045-8

BibTeX
@article{Lee2024,
  author = {Lee, Benjamin J and Griffin, Shawn P and Doh, Jean and Ciurea, Stefan O and Jeyakumar, Deepa and Kongtim, Piyanuch and Naqvi, Kiran},
  title = {Intensification of upfront chemotherapy for patients with myeloid blast phase CML: a single center experience},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-06045-8}
}
Kostenlos starten →